Market Cap | 2.83M | P/E | - | EPS this Y | -40.60% | Ern Qtrly Grth | - |
Income | -17.42M | Forward P/E | -0.04 | EPS next Y | 41.80% | 50D Avg Chg | -88.00% |
Sales | 34.07M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -95.00% |
Dividend | N/A | Price/Book | 0.05 | EPS next 5Y | - | 52W High Chg | -99.00% |
Recommedations | 2.00 | Quick Ratio | 3.58 | Shares Outstanding | 36.83M | 52W Low Chg | 235.00% |
Insider Own | 0.48% | ROA | -22.43% | Shares Float | 19.63M | Beta | 3.93 |
Inst Own | 71.53% | ROE | -47.77% | Shares Shorted/Prior | 173.81K/169.56K | Price | 0.06 |
Gross Margin | -60.89% | Profit Margin | -51.13% | Avg. Volume | 1,492,003 | Target Price | 9.00 |
Oper. Margin | -154.41% | Earnings Date | Aug 2 | Volume | 12,929,980 | Change | 0.00% |
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. On March 27, 2023, Codiak BioSciences, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Howze Yalonda | See Remarks See Remarks | Mar 30 | Sell | 0.1955 | 1,628 | 318 | 7,458 | 03/30/23 |
Sathyanarayanan Sriram | Chief Scientific Off.. Chief Scientific Officer | Mar 29 | Sell | 0.1652 | 11,762 | 1,943 | 03/30/23 | |
Konstantinov Konstantin | Chief Technology Off.. Chief Technology Officer | Mar 28 | Sell | 0.2 | 9,364 | 1,873 | 03/30/23 | |
Bain Linda | Chief Financial Offi.. Chief Financial Officer | Mar 28 | Sell | 0.1693 | 13,412 | 2,271 | 03/30/23 | |
Barna Nicole | See Remarks See Remarks | Mar 29 | Sell | 0.17 | 7,305 | 1,242 | 4,849 | 03/30/23 |
WILLIAMS DOUGLAS E | President & CEO President & CEO | Mar 28 | Sell | 0.18 | 41,667 | 7,500 | 7,655 | 03/30/23 |
Bain Linda | Chief Financial Offi.. Chief Financial Officer | Jan 19 | Sell | 0.58 | 1,880 | 1,090 | 3,120 | 01/23/23 |
Konstantinov Konstantin | Chief Technology Off.. Chief Technology Officer | Jan 19 | Sell | 0.58 | 1,069 | 620 | 1,731 | 01/23/23 |